Overview

Gene Location [1]
12p12.1
Pathway
MAP kinase signaling
Variant Type
Substitution - Missense
Affected Exon Number
3
Gene
KRAS
SIFT Prediction [3]
Deleterious
ClinVar Prediction [3]
Pathogenic

KRAS K117N is present in 0.07% of AACR GENIE cases, with colorectal adenocarcinoma, melanoma, non-small cell lung carcinoma, appendiceal adenocarcinoma, and connective and soft tissue neoplasm having the greatest prevalence [4].

Top Disease Cases with KRAS K117N

Biomarker-Directed Therapies

Significance of KRAS K117N in Diseases

Non-Small Cell Lung Carcinoma +

Colorectal Carcinoma +

Malignant Solid Tumor +

Squamous Cell Lung Carcinoma +

Colorectal Adenocarcinoma +

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Glioma +

Multiple Myeloma +

Small Cell Lung Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.